| Original language | English (US) |
|---|---|
| Pages (from-to) | 384-386 |
| Number of pages | 3 |
| Journal | BJU international |
| Volume | 132 |
| Issue number | 4 |
| DOIs |
|
| State | Published - Oct 2023 |
Keywords
- bacillus Calmette–Guérin
- bladder cancer
- bladder-sparing treatment
- outcomes
- refractory
- relapsing
ASJC Scopus subject areas
- Urology
MD Anderson CCSG core facilities
- Biostatistics Resource Group
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: BJU international, Vol. 132, No. 4, 10.2023, p. 384-386.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Bacillus Calmette–Guérin (BCG) unresponsive non-muscle-invasive bladder cancer
T2 - are the subgroups equal?
AU - Tan, Wei Shen
AU - Grajales, Valentina
AU - Bree, Kelly
AU - Li, Roger
AU - Nogueras-Gonzalez, Graciela M.
AU - Navai, Neema
AU - Dinney, Colin
AU - Kamat, Ashish M.
N1 - Funding Information: Ashish M. Kamat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Ashish M. Kamat is a consultant or advisory board member for Abbott Molecular, Arquer Diagnostics, ArTara Therapeutics, Asieris Pharmaceuticals, AstraZeneca, BioClin Therapeutics, Bristol Myers Squibb, Cepheid, Cold Genesys, Eisai, Engene, Ferring Pharmaceuticals, FerGene, Imagine Pharma, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara Therapeutics, Roviant Sciences, Seattle Genetics, Sessen Bio, Theralase Technologies, TMC Innovation, and US Biotest; has received grants and/or research support from Adolor Corporation, Bristol Myers Squibb, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH, Specialized Programs of Research Excellence (SPORE), and AIBCCR; and holds the patent for Cytokine Predictors of Response to Intravesical Therapy (CyPRIT) jointly with UT MD Anderson Cancer Center. Wei Shen Tan was a consultant to Combat Medical. Kelly Bree was a consultant to Stratify genomics. Roger Li is a consultant to BMS, Ferring, Fergene, Arquer Diagnostics, and Urogen Pharma; has received grant and research support from Predicine, Decipher Biosciences, and CG Oncology. Colin P Dinney receives funding from the Cancer Center Support Grant funding from the National Institutes for Health/National Cancer Institute (award number P30CA016672) at MD Anderson Cancer Center, has received grant and personal fees from FKD Therapies, and is a creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to nadofaragene firadenovec. The other authors have nothing to disclose. Funding Information: This research was supported by the Wayne B. Duddlesten Professorship in Cancer Research, the Raymond and Maria Floyd Bladder Cancer Research Foundation Grant to Ashish M. Kamat, and National Institute of Health/National Cancer Institute UTMD Anderson SPORE in Genitourinary Cancer (Bladder; P50CA091846) to Colin P. Dinney.
PY - 2023/10
Y1 - 2023/10
KW - bacillus Calmette–Guérin
KW - bladder cancer
KW - bladder-sparing treatment
KW - outcomes
KW - refractory
KW - relapsing
UR - http://www.scopus.com/inward/record.url?scp=85161956466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161956466&partnerID=8YFLogxK
U2 - 10.1111/bju.16087
DO - 10.1111/bju.16087
M3 - Comment/debate
C2 - 37246493
AN - SCOPUS:85161956466
SN - 1464-4096
VL - 132
SP - 384
EP - 386
JO - BJU international
JF - BJU international
IS - 4
ER -